
|Videos|October 5, 2022
Urology Times 50 Innovations Series: Multiparametric MRI in prostate cancer
Author(s)Urology Times staff
“From a screening perspective, mpMRI really has changed how we evaluate men at risk for prostate cancer. It has improved the selection of men for biopsy and certainly improved our diagnostic rates,” says William P. Parker, MD.
Advertisement
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, William P. Parker, MD, discusses the use of multiparametric MRI (mpMRI) in prostate cancer. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5


















































